Sana Biotechnology (NASDAQ:SANA) Releases Earnings Results, Misses Expectations By $0.01 EPS

Sana Biotechnology (NASDAQ:SANA) issued its quarterly earnings data on Monday. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01), Zacks reports.

Sana Biotechnology Stock Down 5.5 %

SANA stock traded down $0.16 during mid-day trading on Monday, hitting $2.77. The company had a trading volume of 4,012,056 shares, compared to its average volume of 2,981,883. The company has a market capitalization of $618.46 million, a price-to-earnings ratio of -1.98 and a beta of 1.63. Sana Biotechnology has a 12-month low of $1.52 and a 12-month high of $10.50. The company has a 50-day moving average price of $3.03 and a 200 day moving average price of $3.25.

Insiders Place Their Bets

In other Sana Biotechnology news, insider Fmr Llc sold 290,912 shares of Sana Biotechnology stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total value of $1,888,018.88. Following the completion of the transaction, the insider now directly owns 4,541,511 shares of the company’s stock, valued at $29,474,406.39. This trade represents a 6.02 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 31.10% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. HC Wainwright boosted their price objective on shares of Sana Biotechnology from $8.00 to $11.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. Jefferies Financial Group assumed coverage on shares of Sana Biotechnology in a research report on Friday. They set a “buy” rating and a $7.00 price objective for the company. Finally, TD Cowen raised shares of Sana Biotechnology from a “hold” rating to a “buy” rating in a research report on Wednesday, January 8th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $12.25.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.